Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma 42 Precursor Cell Lymphoblastic Leukemia-Lymphoma 33 Prostatic Neoplasms 32 Lymphoma, Large B-Cell, Diffuse 29 Lymphoma, Follicular 15 Leukemia 15 Lymphoma, Non-Hodgkin 13 Hodgkin Disease 11 Burkitt Lymphoma 10 Leukemia, Biphenotypic, Acute 8 Neoplasm Metastasis 7 Recurrence 6 Neoplasms 6 Lymphoma, Large-Cell, Anaplastic 6 Lymphoma, B-Cell 6 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5 Hemangioma 5 Ovarian Neoplasms 4 Multiple Myeloma 4 Immunoblastic Lymphadenopathy 4 Dendritic Cell Sarcoma, Interdigitating 4 Metastatic Castration-resistant Prostate Cancer 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, T-Cell 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, B-Cell, Marginal Zone 3 Breast Neoplasms 3 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Neurotoxicity Syndromes 2

Interventions

Prednisolone 1 BID protein, human 1 Androgen Antagonists 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Abiraterone Acetate × Prednisolone × Clear all

NCT06768255 2025-01-10

mCRPC

Fudan University

Phase 3 Not yet recruiting

Abiraterone Acetate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡